OncoMatch

OncoMatch/Gastric / Stomach Cancer/PD-L1 (CD274)

Gastric / Stomach CancerPD-L1 (CD274) Clinical Trials

31 recruiting trials·Updated daily from ClinicalTrials.gov

PD-L1 CPS guides selection and expected benefit for first-line chemoimmunotherapy in gastric and GEJ cancer; benefit is strongest at higher CPS, and current labels increasingly restrict use in PD-L1–negative disease. CPS thresholds vary by regimen and have been refined across label updates. Trials investigate novel checkpoint combinations, anti-VEGF plus IO regimens, and second-line IO strategies stratified by PD-L1 CPS.

Match trials to my profileClinician mode →
Top recruiting

Top recruiting PD-L1 (CD274) Gastric / Stomach Cancer trials

Ranked by phase and US site count.

See all trials matched to your profile →
Phase 357 US sites

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

AstraZeneca

Phase 2/Phase 333 US sites

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Bristol-Myers Squibb

Phase 324 US sites

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Astellas Pharma Global Development, Inc.

Phase 318 US sites

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Daiichi Sankyo

Phase 2/Phase 3

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

RemeGen Co., Ltd.

Phase 3

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

FutureGen Biopharmaceutical (Beijing) Co., Ltd

Additional trials

More PD-L1 (CD274) Gastric / Stomach Cancer trials

See all in search →
Phase 2
NCT05482893Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)Phase 1/Phase 211 US sitesNCT04069273Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL AdenocarcinomaPhase 22 US sitesNCT07432295Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)Phase 22 US sitesNCT03526835A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPhase 1/Phase 223 US sitesNCT07115043A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsPhase 1/Phase 26 US sites
Phase 1
16 international trials (no US sites)
NCT04342910Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJCPhase 3NCT06793917Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaPhase 3NCT06346197Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric AdenocarcinomasPhase 3NCT07311408SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy FailurePhase 2NCT05476796Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction CancerPhase 2NCT06036745Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX RegimenPhase 2NCT05536102The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)Phase 2NCT05033392PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction CancerPhase 2NCT06253611First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric CancerPhase 2NCT07149090Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant AscitesPhase 1/Phase 2NCT06468280Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric CancerPhase 2NCT06157996Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscorePhase 2NCT06422403A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced CancersPhase 2NCT07176312Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) PatientsPhase 2NCT07059299A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric AdenocarcinomaPhase 1NCT04999761AB122 Platform StudyPhase 1
Other Gastric / Stomach Cancer biomarkers

Browse other molecular targets with active Gastric / Stomach Cancer trials.

HER2 (ERBB2)FGFR2MMR / MSI-H
← All Gastric / Stomach Cancer clinical trials